Edition:
United Kingdom

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

2.88USD
4:09pm BST
Change (% chg)

$0.21 (+7.87%)
Prev Close
$2.67
Open
$2.71
Day's High
$2.88
Day's Low
$2.66
Volume
13,509
Avg. Vol
60,431
52-wk High
$5.55
52-wk Low
$1.75

Latest Key Developments (Source: Significant Developments)

OncoMed Announces Appointment Of John Lewicki As CEO
Monday, 19 Mar 2018 

March 19 (Reuters) - OncoMed Pharmaceuticals Inc ::ONCOMED ANNOUNCES APPOINTMENT OF JOHN LEWICKI, PHD, AS PRESIDENT, CHIEF EXECUTIVE OFFICER AND A MEMBER OF THE BOARD OF DIRECTORS.ONCOMED PHARMACEUTICALS INC - APPOINTMENT OF JOHN LEWICKI AS PRESIDENT AND CHIEF EXECUTIVE OFFICER OF ONCOMED, EFFECTIVE IMMEDIATELY​.  Full Article

Oncomed Pharmaceuticals Reports Q4 Earnings Per Share $0.25
Thursday, 8 Mar 2018 

March 8 (Reuters) - Oncomed Pharmaceuticals Inc ::Q4 EARNINGS PER SHARE $0.25.Q4 REVENUE $20.6 MILLION VERSUS $6.2 MILLION.ONCOMED PHARMACEUTICALS - CURRENT CASH IS ESTIMATED TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q3 OF 2019.ONCOMED PHARMACEUTICALS SAYS ESTIMATES 2018 OPERATING CASH BURN TO BE ABOUT $55 MILLION, BEFORE CONSIDERING POTENTIAL MILESTONES/OPT-INS - SEC FILING.  Full Article

OncoMed Q4 Earnings Per Share $0.25
Thursday, 8 Mar 2018 

March 8 (Reuters) - OncoMed Pharmaceuticals Inc ::ONCOMED ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q4 EARNINGS PER SHARE $0.25.Q4 REVENUE $20.6 MILLION VERSUS $6.2 MILLION.CURRENT CASH IS ESTIMATED TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q3 OF 2019.Q4 EARNINGS PER SHARE VIEW $-0.33, REVENUE VIEW $5.2 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Oncomed Says Chief Executive Officer Paul Hastings Has Resigned
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Oncomed Pharmaceuticals Inc ::ONCOMED ANNOUNCES CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER PAUL J. HASTINGS HAS RESIGNED.ONCOMED PHARMACEUTICALS INC - IN INTERIM, OFFICE OF PRESIDENT WILL CONTINUE TO PERFORM DUTIES OF PRESIDENT AND CEO.ONCOMED PHARMACEUTICALS INC - BOARD OF DIRECTORS HAS APPOINTED PERRY KARSEN AS CHAIRMAN OF BOARD.  Full Article

OncoMed Estimates 2018 Operating Cash Burn To Be Less Than $55 Mln
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Oncomed Pharmaceuticals Inc ::ONCOMED PROVIDES 2018 OUTLOOK AND 2017 YEAR-END CASH BALANCE AND ANNOUNCES AN UPDATE ON THE ROSMANTUZUMAB PROGRAM.ONCOMED PHARMACEUTICALS INC - YEAR-END 2017 CASH BALANCE OF $103.1 MILLION.ONCOMED PHARMACEUTICALS INC - ‍PRESENTATION OF CLINICAL DATA ON PHASE 1 PROGRAMS EXPECTED IN 2018​.ONCOMED PHARMACEUTICALS - CURRENT CASH ESTIMATED TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q3 2019.ONCOMED - ESTIMATES 2018 OPERATING CASH BURN TO BE LESS THAN $55 MILLION, BEFORE CONSIDERING POTENTIAL MILESTONES/OPT-INS.ONCOMED - ‍TO INITIATE PHASE 1B PORTION OF ITS ANTI-TIGIT TRIAL TO STUDY ANTI-TIGIT IN COMBINATION WITH ANTI-PD1 IN FIRST HALF OF 2018​.  Full Article

Perceptive Advisors reports 6.5 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - PERCEPTIVE ADVISORS LLC :PERCEPTIVE ADVISORS LLC REPORTS A 6.5 PCT PASSIVE STAKE IN ONCOMED PHARMACEUTICALS INC <<>>AS OF NOV 6 - SEC FILING.  Full Article

Oncomed posts Q3 loss per share $0.28
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Oncomed Pharmaceuticals Inc :Oncomed announces third quarter 2017 financial results and operational highlights.Q3 loss per share $0.28.Q3 revenue $5.1 million versus $5.9 million.Oncomed Pharmaceuticals Inc - ‍anticipates 2017 full-year cash utilization will be approximately $90 million​.Oncomed says current cash balance sufficient to fund pipeline development & operations through Q3 2019, before considering potential opt-in milestones​.Oncomed Pharmaceuticals - ‍now plans to initiate Phase 1B portion of anti-tigit trial to study anti-tigit in combination with anti-PD1 in H1 2018​.  Full Article

OncoMed CEO Paul Hastings to take medical leave of absence
Tuesday, 19 Sep 2017 

Sept 19 (Reuters) - OncoMed Pharmaceuticals Inc -:OncoMed chairman and CEO, Paul Hastings, to take medical leave of absence.OncoMed Pharmaceuticals Inc - ‍Hastings will continue to be chief executive officer and chairman of board of directors during his leave of absence​.OncoMed Pharmaceuticals Inc - ‍ in Hastings' absence, co will be led by company's senior management team including creation of an office of president​.  Full Article

OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial
Wednesday, 13 Sep 2017 

Sept 13 (Reuters) - OncoMed Pharmaceuticals Inc :OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial.  Full Article

Oncomed Pharmaceuticals Q2 loss per share $0.40
Wednesday, 2 Aug 2017 

Aug 2 (Reuters) - Oncomed Pharmaceuticals Inc :Oncomed announces second quarter 2017 financial results.Q2 loss per share $0.40.Q2 revenue $6.2 million versus $6.7 million.  Full Article

BRIEF-OncoMed Announces Appointment Of John Lewicki As CEO

* ONCOMED ANNOUNCES APPOINTMENT OF JOHN LEWICKI, PHD, AS PRESIDENT, CHIEF EXECUTIVE OFFICER AND A MEMBER OF THE BOARD OF DIRECTORS